Monday, Relay Therapeutics Inc. RLAY shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ribociclib or atirmociclib (Pfizer Inc’s PFE selective CDK4 inhibitor).The clinical benefit rate (CBR) was 57% in heavily pretreated patients. RLY-2608 is a pan-mutant and isoform-selective inhibitor of PI3Kα.Oppenheimer downgraded Relay Therapeutics, noting the upcoming data from competitors.“We believe that approved PI3K ...